MAINRITSEG: RTX vs. AZA for maintenance in EGPA RTX not superior in primary remission outcome RTX favored in secondary outcome of remission with pred <4mg daily Limitation: only ~50% pt with FFS 1+ @RheumNow #ACR25 Abst 1765 https://t.co/dh5ZWCT12T